Get started
Genfit SAGenfit SAGenfit SA

Genfit SA

No trades
See on Supercharts
OverviewFinancialsNewsIdeasDiscussionsTechnicalsForecastSeasonalsBonds

XUP chart


Full chart

XUP upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪174.64 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.778 EUR
Net income (FY)
‪1.51 M‬ EUR
Revenue (FY)
‪67.00 M‬ EUR
Shares float
‪43.86 M‬
Beta (1Y)
1.24

Employees


Employees (FY)
180
Change (1Y)
+21 +13.21%
Revenue / Employee (1Y)
‪372.23 K‬ EUR
Net income / Employee (1Y)
‪8.37 K‬ EUR

About Genfit SA


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Pascal Prigent
Website
genfit.com
Headquarters
Loos
Founded
1999
ISIN
FR0004163111
FIGI
BBG000QL0432
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné, and Bart Staels in September 1999 and is headquartered in Loos, France.

Check out other big names from the same industry as XUP.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

XUP news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

XUP highest yielding bonds


GNFAA
Genfit S.A. 3.5% 16-OCT-2025
Yield to maturity
—
Maturity date
Oct 16, 2025

See all XUP bonds 

Frequently Asked Questions


The current price of XUP is 3.386 EUR — it has decreased by −0.58% in the past 24 hours. Watch Genfit SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Genfit SA stocks are traded under the ticker XUP.
XUP stock has risen by 12.49% compared to the previous week, the month change is a 3.72% rise, over the last year Genfit SA has showed a −29.38% decrease.
We've gathered analysts' opinions on Genfit SA future price: according to them, XUP price has a max estimate of 9.00 EUR and a min estimate of 5.93 EUR. Watch XUP chart and read a more detailed Genfit SA stock forecast: see what analysts think of Genfit SA and suggest that you do with its stocks.
XUP reached its all-time high on Feb 20, 2015 with the price of 67.392 EUR, and its all-time low was 1.132 EUR and was reached on Nov 22, 2011. View more price dynamics on XUP chart.
See other stocks reaching their highest and lowest prices.
XUP stock is 2.13% volatile and has beta coefficient of 1.24. Track Genfit SA stock price on the chart and check out the list of the most volatile stocks — is Genfit SA there?
Today Genfit SA has the market capitalization of ‪174.31 M‬, it has increased by 5.34% over the last week.
Yes, you can track Genfit SA financials in yearly and quarterly reports right on TradingView.
Genfit SA is going to release the next earnings report on Apr 9, 2026. Keep track of upcoming events with our Earnings Calendar.
XUP earnings for the last half-year are −0.20 EUR per share, whereas the estimation was 1.02 EUR, resulting in a −119.51% surprise. The estimated earnings for the next half-year are −0.24 EUR per share. See more details about Genfit SA earnings.
Genfit SA revenue for the last half-year amounts to ‪35.70 M‬ EUR, despite the estimated figure of ‪98.55 M‬ EUR. In the next half-year revenue is expected to reach ‪31.30 M‬ EUR.
XUP net income for the last half-year is ‪−9.96 M‬ EUR, while the previous report showed ‪−28.80 M‬ EUR of net income which accounts for 65.44% change. Track more Genfit SA financial stats to get the full picture.
No, XUP doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 7, 2025, the company has 180 employees. See our rating of the largest employees — is Genfit SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Genfit SA EBITDA is ‪−29.54 M‬ EUR, and current EBITDA margin is 2.07%. See more stats in Genfit SA financial statements.
Like other stocks, XUP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Genfit SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Genfit SA technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Genfit SA stock shows the sell signal. See more of Genfit SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.